SCHEMBL23218293

SCHEMBL23218293

c1cnc2c(c1)ccc1ccsc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.58
LMNA P02545 3/20 0.58
CCR1 P32246 3/20 0.58
CCR5 P51681 3/20 0.58
CCR8 P51685 3/20 0.58
MMP2 P08253 3/20 0.58
TSHR P16473 2/20 0.58
ALOX15 P16050 2/20 0.58
MAPT P10636 2/20 0.58
TDP1 Q9NUW8 2/20 0.58
GMNN O75496 1/20 0.58
TP53 P04637 1/20 0.58
HSP90AA1 P07900 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
MMP9 P14780 1/20 0.58
NFKB1 P19838 1/20 0.58
MMP8 P22894 1/20 0.58
THPO P40225 1/20 0.58
MTOR P42345 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenanthroline SCHEMBL725644 0.78 CCR1 (0.94) KDM4ELMNACCR1CCR5CCR8
Phenanthroline SCHEMBL28973442 0.78 CCR1 (0.94) KDM4ELMNACCR1CCR5CCR8
Phenanthroline SCHEMBL31040598 0.78 CCR1 (0.94) KDM4ELMNACCR1CCR5CCR8
Phenanthroline SCHEMBL4901390 0.78 CCR1 (0.94) KDM4ELMNACCR1CCR5CCR8
SCHEMBL8599120 0.76 KDM4E (0.51) KDM4ELMNACCR1CCR5CCR8
Phenanthroline SCHEMBL996092 0.75 CCR1 (0.89) KDM4ELMNACCR1CCR5CCR8
Phenanthroline SCHEMBL30165588 0.75 CCR1 (0.89) KDM4ELMNACCR1CCR5CCR8
Phenanthroline SCHEMBL8324317 0.75 CCR1 (0.89) KDM4ELMNACCR1CCR5CCR8
Phenanthroline SCHEMBL1237620 0.75 CCR1 (0.89) KDM4ELMNACCR1CCR5CCR8
Phenanthroline SCHEMBL8312 0.75 CCR1 (1.00) KDM4ELMNACCR1CCR5CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB KDM4E 4172/4885LMNA 1698/4885CCR1 91/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB KDM4E 4491/4885LMNA 1844/4885CCR1 753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.